TheraCryf PLCLSE: TCF

TheraCryf: Investor Conference Attendance

· Issued by TheraCryf PLC via RNS

Summary by 6ix AI

TheraCryf plc, a biotechnology company developing medicines for addiction and other neuropsychiatric disorders, will present at two London investor events on November 16 to 18, 2026, where management will meet shareholders and prospective investors and answer questions about the company and its lead Ox-1 addiction programme.

Key details

  • Chief Executive Officer Dr Huw Jones will present at the LSX Investival Showcase at Old Billingsgate, London, on November 16, 2026, at 11.45 am.
  • TheraCryf will attend Mello London at the Clayton Hotel & Conference Centre, Chiswick, London, presenting from 10.40-11.10 am on Tuesday, November 17, 2026 and from 2.25-2.55 pm on Wednesday, November 18, 2026.
  • The company says the presentations will draw on information already public and no new material information will be disclosed.
  • Management attended BIO-Europe in Cologne from November 9 to 11, 2026, meeting potential partners and industry colleagues to discuss TheraCryf's development programmes.

6ix AI wrote this summary from the release below and checked it against the release.

Theracryf PLC
16 November 2026

16 November 2026

TheraCryf plc

(“TheraCryf”, the “Company” or the “Group”)

Investor Conference Attendance

TheraCryf plc (AIM: TCF), the biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, is pleased to announce its participation in the following investor conferences.

Management will be available to meet existing shareholders and prospective investors and answer questions about TheraCryf and its lead Ox-1 addiction programme.

LSX Investival Showcase – 16 November 2026

Dr Huw Jones, Chief Executive Officer, will present at the LSX Investival Showcase at Old Billingsgate, London, today, 16 November 2026, at 11.45 am.

Further information is available at: https://informaconnect.com/investival-showcase/

Mello London – 17–18 November 2026

TheraCryf will attend Mello London at the Clayton Hotel & Conference Centre, Chiswick, London, on Tuesday, 17 November 2026 and Wednesday, 18 November 2026.

The Company will present from 10.40-11.10 am on Tuesday, 17 November 2026 and from 2.25-2.55 pm on Wednesday, 18 November 2026.

For further information and tickets (use code SHAREML25 for 25% off ticket price), please visit the event website at www.melloevents.com/mellolondon2026

These events follow the Company’s attendance at BIO-Europe in Cologne from 9–11 November 2026, where management met potential partners and industry colleagues to discuss TheraCryf’s development programmes.

The presentations will draw on information already in the public domain. No new material information will be disclosed.

-Ends-

Enquiries

TheraCryf plc

Dr Huw Jones, CEO

Toni Hänninen, CFO

Dr Helen Kuhlman, COO

+44 (0)1625 315 090

enquiries@theracryf.com

Strand Hanson (Financial & Nominated Adviser)
James Harris / Carl Holmes / Imogen Ellis / Harry Hiley

+44 (0)20 7409 3494

Turner Pope Investments (Broker)

Andy Thacker / Guy McDougall

+44 (0)20 3657 0050

Northstar Communications (Investor Relations)

Sarah Hollins

+44 (0)113 730 3896

sarah@northstarcommunications.co.uk

About TheraCryf

TheraCryf plc is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of significant unmet medical need.

The Group’s lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders.

The programme has already been heavily de-risked for both safety/tolerability and efficacy in previous testing and is fully funded through final pre-clinical trials to clinical readiness, with regulatory submissions for first in man studies targeted for 2026.

TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01.

The Group operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with commercially focused pharmaceutical and biotechnology companies.

TheraCryf’s headquarters and registered office are at Alderley Park, Cheshire.

For further information, visit: https://theracryf.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TheraCryf PLC on 6ix

Story so far

Earlier from TheraCryf

Later from TheraCryf

All TheraCryf news releases